SERA

Serimmune to Lead Discussion on Advances in Vaccine Development at Vaccine Summit 2023

Retrieved on: 
Wednesday, November 8, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, SERA, Epitope, Manhattan Center, Vaccine, Research

Whether studying longitudinal samples, novel formulations of vaccines or boosters, pre-clinical vs. clinical vaccine responses, or vaccine vs. natural infection, SERA enables comparative, high-throughput, high-resolution analysis of epitopes to enable precision immunology, supporting the next generation of vaccine development.

Key Points: 
  • Whether studying longitudinal samples, novel formulations of vaccines or boosters, pre-clinical vs. clinical vaccine responses, or vaccine vs. natural infection, SERA enables comparative, high-throughput, high-resolution analysis of epitopes to enable precision immunology, supporting the next generation of vaccine development.
  • WHO: Serimmune and Vaccine Summit 2023 will bring together experts in the field of vaccine research as well as industry leaders to address current issues facing vaccine development.
  • The “New Vaccine Development” session will be led by Dr. John Shon, Chief Technology Officer, Serimmune.
  • WHERE: Vaccine Summit 2023 at the Sheraton Boston Needham Hotel, Grand Ballroom.

Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

Retrieved on: 
Wednesday, October 4, 2023
Health, Biometrics, Other Health, Other Science, Research, Science, Pharmaceutical, University, Therapy, Regeneron Pharmaceuticals, Arena Pharmaceuticals, Quality of life, Orthostatic hypertension, Bristol Myers Squibb, MBA, SERA, Ulcerative colitis, Atrasentan, Patient, Sanofi, Biology, Jan Vansina, Chronic kidney disease, Safety, Pharmaceutical industry, Chinook

Nuvig Therapeutics, Inc. , a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.

Key Points: 
  • Nuvig Therapeutics, Inc. , a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.
  • He is passionate about improving the health and quality of life for patients,” said Julie Anne Smith, Chief Executive Officer of Nuvig Therapeutics.
  • I look forward to working with the high-caliber team at Nuvig to advance our clinical programs to maximize the therapeutic impact of this incredible opportunity in medicine.”
    Prior to Nuvig, Dr. Glicklich was the Chief Medical Officer at Chinook Therapeutics, where he focused on biologics and small molecules for rare, chronic kidney diseases.
  • Before working at Chinook, Dr. Glicklich was the Chief Medical Officer at Bird Rock Bio, focusing on monoclonal antibody development for inflammatory and fibrotic diseases.

Serimmune Announces Use of Its SERA Platform in Study Designed to Identify Features of Long COVID Through Immune Profiling

Retrieved on: 
Tuesday, October 3, 2023
Other Health, Research, General Health, Pharmaceutical, Infectious Diseases, Health Technology, Clinical Trials, Science, COVID-19, Biotechnology, FDA, Health, Long COVID, Antigen, ELISA, Friends, SARS-CoV-2, Quality of life, Brain, Disease, COVID, Doctor of Philosophy, SERA, Government, CDC, Machine learning, Blood, Korea Disease Control and Prevention Agency, Epitope, System, EBV, Fatigue, Vaccine, Nature, MD

In the article titled, “Distinguishing features of Long COVID identified through immune profiling,” the authors describe how complementary approaches, including Serimmune's SERA platform and enzyme-linked immunosorbent assay (ELISA) were used to examine antiviral reactivity patterns in participants.

Key Points: 
  • In the article titled, “Distinguishing features of Long COVID identified through immune profiling,” the authors describe how complementary approaches, including Serimmune's SERA platform and enzyme-linked immunosorbent assay (ELISA) were used to examine antiviral reactivity patterns in participants.
  • Findings from the study showed that individuals with Long COVID have elevated antibody responses directed against both SARS-CoV-2 and non-SARS-CoV-2 viral antigens, particularly Epstein-Barr virus (EBV) antigens.
  • A recent report from the Centers for Disease Control and Prevention (CDC) found that even though the rate of Long COVID is declining, one in four adults with Long COVID struggle to perform activities-of-daily-living.
  • “We are driven to improve the way diseases like Long COVID are diagnosed and treated through our state-of-the-art immunology, next generation sequencing, bioinformatics and machine learning.

SIERRA NORTHERN RAILWAY AND PARTNERS CONDUCT PUBLIC BRIEFING ON ZERO EMISSION SWITCHING LOCOMOTIVE

Retrieved on: 
Tuesday, January 24, 2023
Hydrogen, Carbon, California Energy Commission, LCRI, Sierra Northern Railway, Nation, History of the Federated States of Micronesia, Particulates, Multimedia, NOx, State, Ballard Power Systems, Quality of life, SERA, Southern California Gas Company, Oil

WEST SACRAMENTO, Calif., Jan. 10, 2023 /PRNewswire/ -- Sierra Northern Railway and partner Valley Vision conducted a public briefing of their Zero Emission Hydrogen Switching locomotive.

Key Points: 
  • WEST SACRAMENTO, Calif., Jan. 10, 2023 /PRNewswire/ -- Sierra Northern Railway and partner Valley Vision conducted a public briefing of their Zero Emission Hydrogen Switching locomotive.
  • The online briefing outlined how the Sierra Northern Railway Zero Emission Locomotive will be transformative providing essential services for America's railroads by proving the hydrogen-fueled units capable of improving air quality, reducing greenhouse gas emissions, and increasing the quality of life in surrounding communities.
  • Sierra has a stated goal of having the first zero emission switching fleet in the nation and commercializing its technology to lead the industry into the zero-emission future.
  • Sierra Northern Railway (SERA) the technical lead, partnering with GTI Energy as the formal applicant to the California Energy Commission.

Systems Oncology to Present Positive Preclinical Data for SERA2 at J.P. Morgan 41st Annual Healthcare Conference

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, ER, Chemistry, Baylor University Medical Center, UPR, Champaign County, Illinois, Oncology, J. P. Morgan, Intellectual property, IP, Patient, SERA, Research, Biology, Breast cancer, SO, Aromatase, Unfolded protein response, Selective estrogen receptor degrader, McKesson Corporation, Cell death, University, Selective estrogen receptor modulator, Medical imaging, Pharmaceutical industry

Systems Oncology today announced they will be presenting positive preclinical data on the companys next generation estrogen receptor positive drug candidate, SERA2 (Selective Estrogen Receptor Activator).

Key Points: 
  • Systems Oncology today announced they will be presenting positive preclinical data on the companys next generation estrogen receptor positive drug candidate, SERA2 (Selective Estrogen Receptor Activator).
  • In the preclinical data presented at J.P. Morgan, treatment with SERA2 in animal models of human breast cancer results in multiple, complete, durable tumor regressions.
  • These data support the rationale for SERA2 as a novel therapeutic for the treatment of breast cancer and potentially other estrogen receptor positive cancers.
  • Systems Oncology will be having partnering meetings during the J.P. Morgan conference from January 9 to January 11, 2023.

HHS and the Cohen Foundation Name Serimmune a Phase 1 Winner in LymeX Diagnostics Prize

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Health, Philanthropy, General Health, State, Local, Research, Infectious Diseases, Foundation, Public Policy, Government, Science, Clinical Trials, Epitope, LabCorp, Antigen, Infection, Immunity, Database, Human services, Machine learning, Vaccine, Lyme disease, Office of Inspector General, U.S. Department of Health and Human Services, Microfluidics, Therapy, HHS, COVID-19, Map, U.S. Department of Defense Strategy for Operating in Cyberspace, SERA, Antibody, Merck

The U.S. Department of Health and Human Services and the Cohen Foundation have selected Serimmune as a Phase 1 winner in the LymeX Diagnostics Prize , a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics.

Key Points: 
  • The U.S. Department of Health and Human Services and the Cohen Foundation have selected Serimmune as a Phase 1 winner in the LymeX Diagnostics Prize , a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics.
  • As a Phase 1 winner, Serimmune will receive $100,000 and an invitation to participate in a second phase.
  • At the discretion of HHS and the Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2.
  • Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Cohen Foundation, $9 million in additional LymeX prizes are projected to be available in proposed future phases.

Sierra Northern Railway unveils new Hydrogen Powered, Zero Emission Switching Locomotive design concept

Retrieved on: 
Wednesday, September 7, 2022
Hydrogen, Zero, Carbon, Technology, Research, Ballard Power Systems, Sierra, Solution, Heart, Southern California Gas Company, Golden State, LCRI, Golden State League, GTI, State, Hydrogen-powered aircraft, LLC, Sierra Northern Railway, Efficiency, California Energy Commission, SERA, BNSF Railway, Industry, Transport, Union Pacific Railroad, Noise, GHG, Rail transport, Oil

SACRAMENTO, Calif., Sept. 7, 2022 /PRNewswire/ -- Sierra Northern Railway (SERA) unveiled the new look for its industry-leading Hydrogen Powered Switching Locomotive.

Key Points: 
  • SACRAMENTO, Calif., Sept. 7, 2022 /PRNewswire/ -- Sierra Northern Railway (SERA) unveiled the new look for its industry-leading Hydrogen Powered Switching Locomotive.
  • "We are pleased to present this new look for the Sierra Northern Railway Zero Emission Hydrogen Switching Locomotive as we continue to refine our design and prepare to build and test the locomotive.
  • We are more convicted today than ever that the Sierra Northern Railway Zero Emission Hydrogen Switching Locomotive will help ensure the switching locomotive industry will have a zero-emission solution in the near future," said Kennan H. Beard III, President of Sierra Northern Railway.
  • Sierra Northern Railway (SERA): Sierra Northern Railway is the freight division of privately-owned, Sierra Railroad Company.

Embry-Riddle Selects SERA and Pilot PT for Aviation English and Virtual Reality Training

Retrieved on: 
Thursday, March 3, 2022
Cloud, Student, Intelligence, Tablet, Immersion, Radio, Safety, Aviation, Meteorology, Asti, FAA, Embry–Riddle Aeronautical University, Realism, Air traffic control, U.S. News & World Report, Communication, Newsroom, EASA, Engineering, Technology, Operation, AI, News, SERA, PILOT, ATC, Astronomy, Airline, Satellite navigation device

The Pre-flight Immersion Laboratory for Operations Training (PILOT) program focuses on aviation English, addressing a recently identified FAA concern covering the broad spectrum of aviation communication skills.

Key Points: 
  • The Pre-flight Immersion Laboratory for Operations Training (PILOT) program focuses on aviation English, addressing a recently identified FAA concern covering the broad spectrum of aviation communication skills.
  • The Pilot Phraseology Trainer (Pilot PT) is a web-based tool that uses in-house speech recognition and ASTi's advanced text-to-speech system focused on aviation English.
  • Moving on to the final stage of radio training, students enter a virtual reality flight on a flight training device, where they can test their skills with SERA.
  • The phraseology and radio calls students learn using Pilot PT matches what they hear in a SERA flight, providing a consistent training experience.

Serimmune and Mymee Collaborate on Research Study to Better Define the Role of Antibodies in SARS-CoV-2 Symptoms

Retrieved on: 
Tuesday, September 21, 2021
Research, Technology, Infectious Diseases, Other Technology, Clinical Trials, Software, Biotechnology, Health, Data Management, Science, Partnership, Vaccine, Degenerative disease, Fatigue, Therapy, Health, Immunity, Map, Fast Company, Multimedia, Patient, Database, CEO, Autoimmunity, COVID, Antibody, Pain, Risk, Vaccination, Mount Sinai Hospital, COVID-19, Technology, Inflammation, Antigen, Diet, Severe acute respiratory syndrome coronavirus 2, Research, Disease, Infection, Brain, Autoimmune disease, SERA, Machine learning, Quality of life, Survivor, LabCorp, Serimmune, Mymee, SERIMMUNE, MYMEE

The partnership includes collaborating on research to understand the presence of antibodies in people with autoimmunity, including disease activity and those most at risk.

Key Points: 
  • The partnership includes collaborating on research to understand the presence of antibodies in people with autoimmunity, including disease activity and those most at risk.
  • This data will help researchers better understand how variations in antibody response may influence COVID-19 symptoms from very mild to severe.
  • Serimmune is a leader in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens.
  • 79% Mymee members see reductions in common autoimmunity symptoms like fatigue, brain fog and pain within the first 8 weeks.